PPARδ agonism induces a change in fuel metabolism and activation of an atrophy programme, but does not impair mitochondrial function in rat skeletal muscle
- 7 August 2007
- journal article
- research article
- Published by Wiley in The Journal of Physiology
- Vol. 583 (1) , 381-390
Abstract
PPARα agonism impairs mitochondrial function, but the effect of PPARδ agonism on mitochondrial function is equivocal. Furthermore, PPARα and δ agonism increases muscle fatty acid oxidation, potentially via activation of FOXO1 signalling and PDK4 transcription. Since FOXO1 activation has also been suggested to increase transcription of MAFbx and MuRF‐1, and thereby the activation of ubiquitin–proteasome mediated muscle proteolysis, this raises the possibility that muscle fuel selection and the induction of a muscle atrophy programme could be regulated by a single common signalling pathway. We therefore investigated the effect of PPARδ (delta) agonist, GW610742, administration on muscle mitochondrial function, fuel regulation, and atrophy and growth related signalling pathways in vivo. Twenty‐four male Wistar rats received vehicle or GW610742 (5 and 100 mg per kg body mass (bm)) orally for 6 days. Soleus muscle was used to determine maximal rates of ATP production (MRATP) in isolated mitochondria, gene and protein expression, and enzyme activities. MRATP were unchanged by GW610742. Muscle PDK2 and PDK4 mRNA expression increased with GW610742 (100 mg (kg bm)−1) compared to vehicle (P < 0.05), and was paralleled by a twofold increase in PDK4 protein expression (P < 0.05). The activity of β‐hydroxyacyl‐CoA dehydrogenase increased with GW610742 (P < 0.05). Muscle MuRF1 and MAFbx mRNA expression was increased by GW610742 (100 mg (kg bm)−1) compared to vehicle (P < 0.05), and was matched by increased protein expression (P < 0.001), whilst Akt1 protein declined (P < 0.05). There was no effect of GW610742 on 20S proteasome activity and mRNA expression, or the muscle DNA: protein ratio. GW610742 switched muscle fuel metabolism towards decreased carbohydrate use and enhanced lipid utilization, but did not induce mitochondrial dysfunction. Furthermore, GW610742 initiated a muscle atrophy programme, possibly via changes in the Akt1/FOXO/MAFbx and MuRF1 signalling pathway.Keywords
This publication has 38 references indexed in Scilit:
- PPARδ, but not PPARα, activates PGC-1α gene transcription in muscleBiochemical and Biophysical Research Communications, 2007
- Akt signalling through GSK‐3β, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophyThe Journal of Physiology, 2006
- A signaling role for dystrophin: Inhibiting skeletal muscle atrophy pathwaysCancer Cell, 2005
- Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cellsThe FEBS Journal, 2005
- Regulation of Muscle Fiber Type and Running Endurance by PPARδPLOS Biology, 2004
- Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivationBiochemical Journal, 2003
- Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injectionFEBS Letters, 2003
- Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activityBioorganic & Medicinal Chemistry Letters, 2003
- Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor αBiochemical and Biophysical Research Communications, 2001
- Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agentsToxicology, 1992